173 related articles for article (PubMed ID: 35878026)
21. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
Jaigirdar A; Rosenberg SA; Parkhurst M
J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
[TBL] [Abstract][Full Text] [Related]
22. Unraveling a hotspot for TCR recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinants.
Gagnon SJ; Borbulevych OY; Davis-Harrison RL; Baxter TK; Clemens JR; Armstrong KM; Turner RV; Damirjian M; Biddison WE; Baker BM
J Mol Biol; 2005 Oct; 353(3):556-73. PubMed ID: 16197958
[TBL] [Abstract][Full Text] [Related]
23. Identification of T helper epitopes from prostatic acid phosphatase.
McNeel DG; Nguyen LD; Disis ML
Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
[TBL] [Abstract][Full Text] [Related]
24. Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition.
Schneidman-Duhovny D; Khuri N; Dong GQ; Winter MB; Shifrut E; Friedman N; Craik CS; Pratt KP; Paz P; Aswad F; Sali A
PLoS One; 2018; 13(11):e0206654. PubMed ID: 30399156
[TBL] [Abstract][Full Text] [Related]
25. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
[TBL] [Abstract][Full Text] [Related]
26. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
27. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
[TBL] [Abstract][Full Text] [Related]
28. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
29. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.
Thomas S; Xue SA; Bangham CR; Jakobsen BK; Morris EC; Stauss HJ
Blood; 2011 Jul; 118(2):319-29. PubMed ID: 21606483
[TBL] [Abstract][Full Text] [Related]
30. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
31. Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays.
Wu X; Xu X; Gu R; Wang Z; Chen H; Xu K; Zhang M; Hutton J; Yang T
Autoimmunity; 2012 Mar; 45(2):176-85. PubMed ID: 22260783
[TBL] [Abstract][Full Text] [Related]
32. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
[TBL] [Abstract][Full Text] [Related]
33. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma.
Wang Y; Harada M; Yano H; Ogasawara S; Takedatsu H; Arima Y; Matsueda S; Yamada A; Itoh K
J Immunother; 2005; 28(6):535-41. PubMed ID: 16224270
[TBL] [Abstract][Full Text] [Related]
34. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
Stone JD; Harris DT; Kranz DM
Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the human CD4(+) T-cell repertoire specific for major histocompatibility class I-restricted antigens.
Legoux F; Gautreau L; Hesnard L; Leger A; Moyon M; Devilder MC; Bonneville M; Saulquin X
Eur J Immunol; 2013 Dec; 43(12):3244-53. PubMed ID: 23963968
[TBL] [Abstract][Full Text] [Related]
37. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
[TBL] [Abstract][Full Text] [Related]
38. How an alloreactive T-cell receptor achieves peptide and MHC specificity.
Wang Y; Singh NK; Spear TT; Hellman LM; Piepenbrink KH; McMahan RH; Rosen HR; Vander Kooi CW; Nishimura MI; Baker BM
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4792-E4801. PubMed ID: 28572406
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
Front Immunol; 2019; 10():2076. PubMed ID: 31552033
[TBL] [Abstract][Full Text] [Related]
40. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
Robbins PF; Li YF; El-Gamil M; Zhao Y; Wargo JA; Zheng Z; Xu H; Morgan RA; Feldman SA; Johnson LA; Bennett AD; Dunn SM; Mahon TM; Jakobsen BK; Rosenberg SA
J Immunol; 2008 May; 180(9):6116-31. PubMed ID: 18424733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
